The global healthcare landscape is currently witnessing a profound structural realignment, as the specialised sector of women’s health technology, femtech, transitions from a niche venture category into a cornerstone of institutional investment and public market interest. As the industry moves through the 2026–2027 window, the convergence of clinical-grade digital platforms, advanced molecular diagnostics, and the aggressive integration of artificial intelligence has created

The European healthcare technology and medical device sectors have reached a definitive inflection point in 2026, transitioning from a decade of speculative, venture-subsidised experimentation to an era of disciplined industrial maturity. This report provides an analysis of the structural drivers of this consolidation, the emergence of the Founder Banker as the primary architect of liquidity and the technological and regulatory forces shaping the M&A landscape in 2026.